Unknown PHASE1 INTERVENTIONAL 1-arm NCT01716364

Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase I Study Investigating Safety Immunological Effects of Peripheral Blood T Lymphocytes Transduced With Anti LewisY Chimeric Receptor Gene in LewisY Positive Myeloma, Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Sponsor: Peter MacCallum Cancer Centre, Australia

Conditions Acute Myeloid Leukaemia Multiple Myeloma Myelodysplastic Syndrome

Interventions Anti-LeY- scFv-CD28-ζ vector,.

Updated 5 times since 2017 Last updated: Dec 3, 2012 Started: Jan 31, 2010 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Acute Myeloid Leukaemia and Multiple Myeloma, this trial is ongoing. The trial is conducted by Peter MacCallum Cancer Centre, Australia and has accumulated 5 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peter MacCallum Cancer Centre, Australia

Data source: Peter MacCallum Cancer Centre, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia